Hybrid Molecules of Benzothiazole and Hydroxamic Acid as Dual-Acting Biofilm Inhibitors with Antibacterial Synergistic Effect against Pseudomonas aeruginosa Infections
Zhen-Meng Zhang, Si-Yu Zhao, Wen-Qian Liu, Xiao Wu, Jie Tang, Yu-Jie Li, Xi-Bing Hu, Ying-Bo Zhou, Li-Xuan Dai, Mei-Yan Huang, Ping Lan, Ping-Hua Sun, Jun Xu*, Jun Liu* and Jun-Xia Zheng*,
{"title":"Hybrid Molecules of Benzothiazole and Hydroxamic Acid as Dual-Acting Biofilm Inhibitors with Antibacterial Synergistic Effect against Pseudomonas aeruginosa Infections","authors":"Zhen-Meng Zhang, Si-Yu Zhao, Wen-Qian Liu, Xiao Wu, Jie Tang, Yu-Jie Li, Xi-Bing Hu, Ying-Bo Zhou, Li-Xuan Dai, Mei-Yan Huang, Ping Lan, Ping-Hua Sun, Jun Xu*, Jun Liu* and Jun-Xia Zheng*, ","doi":"10.1021/acs.jmedchem.4c0251710.1021/acs.jmedchem.4c02517","DOIUrl":null,"url":null,"abstract":"<p >The ubiquitous opportunistic pathogen <i>Pseudomonas aeruginosa</i> (<i>P. aeruginosa</i>) causes biofilm-associated drug-resistant infections that often lead to treatment failure. Targeting the bacterium’s quorum sensing (QS) and iron homeostasis presents a promising strategy to combat biofilm formation. This study synthesized benzothiazole-conjugated hydroxamic acid derivatives as dual-acting biofilm inhibitors, and compound <b>JH21</b> was identified as the hit compound with potent submicromolar biofilm inhibitory activity (IC<sub>50</sub> = 0.4 μM). Further mechanistic studies demonstrated not only that the production of virulence was decreased through mainly inhibiting QS system but also that <b>JH21</b> competed for iron with the high-affinity siderophore pyoverdine, inducing iron deficiency and inhibiting biofilm. Moreover, <b>JH21</b> significantly enhanced the efficacy of tobramycin and ciprofloxacin by 200- and 1000-fold, respectively, in a mouse wound infection model. These results emphasized the feasibility of dual-acting biofilm inhibitors against resistant <i>P. aeruginosa</i> infections and the potential of <b>JH21</b> as a novel antibacterial synergist.</p>","PeriodicalId":46,"journal":{"name":"Journal of Medicinal Chemistry","volume":"68 6","pages":"6210–6232 6210–6232"},"PeriodicalIF":6.8000,"publicationDate":"2025-03-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Medicinal Chemistry","FirstCategoryId":"3","ListUrlMain":"https://pubs.acs.org/doi/10.1021/acs.jmedchem.4c02517","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
The ubiquitous opportunistic pathogen Pseudomonas aeruginosa (P. aeruginosa) causes biofilm-associated drug-resistant infections that often lead to treatment failure. Targeting the bacterium’s quorum sensing (QS) and iron homeostasis presents a promising strategy to combat biofilm formation. This study synthesized benzothiazole-conjugated hydroxamic acid derivatives as dual-acting biofilm inhibitors, and compound JH21 was identified as the hit compound with potent submicromolar biofilm inhibitory activity (IC50 = 0.4 μM). Further mechanistic studies demonstrated not only that the production of virulence was decreased through mainly inhibiting QS system but also that JH21 competed for iron with the high-affinity siderophore pyoverdine, inducing iron deficiency and inhibiting biofilm. Moreover, JH21 significantly enhanced the efficacy of tobramycin and ciprofloxacin by 200- and 1000-fold, respectively, in a mouse wound infection model. These results emphasized the feasibility of dual-acting biofilm inhibitors against resistant P. aeruginosa infections and the potential of JH21 as a novel antibacterial synergist.
期刊介绍:
The Journal of Medicinal Chemistry is a prestigious biweekly peer-reviewed publication that focuses on the multifaceted field of medicinal chemistry. Since its inception in 1959 as the Journal of Medicinal and Pharmaceutical Chemistry, it has evolved to become a cornerstone in the dissemination of research findings related to the design, synthesis, and development of therapeutic agents.
The Journal of Medicinal Chemistry is recognized for its significant impact in the scientific community, as evidenced by its 2022 impact factor of 7.3. This metric reflects the journal's influence and the importance of its content in shaping the future of drug discovery and development. The journal serves as a vital resource for chemists, pharmacologists, and other researchers interested in the molecular mechanisms of drug action and the optimization of therapeutic compounds.